London, England -- (ReleaseWire) -- 03/16/2012 -- GlobalData’s analysis shows that the global osteopenia therapeutics market stood at $1.6 billion in 2006 and grew at a Compound Annual Growth Rate (CAGR) of 4.6% to reach $2.0 billion in 2011. GlobalData forecasts that the global osteopenia therapeutics market will grow moderately at a CAGR of 2.9% over the next eight years to reach $2.7 billion by 2019. The current competitive landscape consists mainly of bisphosphonates, Selective Estrogen Receptor Modulators (SERM) and hormone therapy including estrogen and its derivatives. The expected moderate growth can be attributed to an increase in awareness, an ageing population and the launch of newer formulations of currently marketed products.
The impending patent expiry of Boniva (ibandronate) in 2012; Actonel (risedronate sodium) and Reclast (zoledronic acid) in 2013; and Evista (raloxifene) in 2014 will allow patients to access treatment at a much lower cost; however, it will also result in the brand erosion of these drugs. The growth in the historic period was also affected by Fosamax (alendronate) generics, which lost its patent exclusivity in 2008.
GlobalData assessed the current competitive landscape for osteopenia drugs and found that the competition is strong. The market has several therapeutic options for the management of osteopenia, which includes bisphosphonates such as alendronate, Actonel, Reclast and Boniva as the first line of therapy and SERMs such as Evista and other drugs containing hormones (estrogen/progesterone). Current treatment options in osteopenia therapeutics have comparable efficacy levels and safety profiles, with only marginal differences; this has intensified the competition in the market. However, these agents do not completely satisfy the patients’ needs; there is a large percentage of people looking for better treatment options in terms of safety, efficacy and dosage patterns for better compliance. Such patients do not have a choice but to continue with the presently available drugs, even though they do not meet their needs sufficiently. Any drug that could successfully cater to the needs of this patient segment is expected to capture a major revenue share of the osteopenia therapeutics market.
For Sample Pages, please click or add the below link to your browser:
GlobalData’s analysis shows that the osteopenia therapeutics pipeline is strong with 14 molecules in the various phases of clinical development. There are three products which are awaiting regulatory approval from the US Food and Drug Administration (FDA) and European Medicines Agency (EMEA). They are Fablyn (bazedoxifene), Viviant (lasofoxifene) and EX101 (alendronate in effervescent form). Fablyn and Viviant have been filed for approval with the US FDA.
As osteopenia has a significant impact on a patient’s Quality Of Life (QOL), companies must prioritize Research and Development (R&D) in order to identify new molecules for the prevention and treatment of this disease. This will facilitate the discovery of new molecules with novel disease-targeting mechanisms of action for clinical development. GlobalData also expects that the osteopenia therapeutics market is experiencing a shift towards combination products, using two or more effective osteopenia treatments.
GlobalData, the industry analysis specialist, has released its new report, “Osteopenia Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global osteopenia therapeutics market. The report identifies the key trends shaping and driving the global osteopenia therapeutics market. It also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global osteopenia therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
For further details, please click or add the below link to your browser:
Visit our report store: http://www.globaldata.com/reportstore
For more details contact:
North America: +1 646 395 5477
+44 207 753 4299
+44 1204 543 533
+91 40 6616 6782